CoChat

Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1

Open access

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

E74-like ETS transcription factor 5 (ELF5) is involved in a wide spectrum of biological processes, e.g., mammogenesis and tumor progression. We have identified a list of p300-interacting proteins in human breast cancer cells. Among these, ELF5 was found to interact with p300 via acetylation, and the potential acetylation sites were identified as K130, K134, K143, K197, K228, and K245. Furthermore, an ELF5-specific deacetylase, SIRT6, was also identified. Acetylation of ELF5 promoted its ubiquitination and degradation, but was also essential for its antiproliferative effect against breast cancer, as overexpression of wild-type ELF5 and sustained acetylation-mimicking ELF5 mutant could inhibit the expression of its target gene CCND1. Taken together, the results demonstrated a novel regulation of ELF5 as well as shedding light on its important role in modulation of breast cancer progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41698-021-00158-3

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Identification of ELF5 from p300 interaction network. a Silver-staining of p300 interacted protein. MCF7 cell lysis and T47D cell lysis were prepared and subjected to affinity purification using anti-p300 antibody or normal IgG. The purified proteins were resolved by SDS-PAGE and visualized by silver-staining. The protein bands were excised and analyzed by mass spectrometry. b ELF5 was immunoprecipitated with p300. Whole-cell lysates from T47D cells were subjected to co-immunoprecipitation performed with anti-p300 antibody or normal IgG followed by immunoblotting with performed with the indicated antibodies. Enrichment analysis (c) and cluster analysis (d) of biological processes according to the results of mass spectrometry. The graphs were downloaded from http://metascape.org/. e, f Comparison of ELF5 mRNA expression in healthy and various cancer tissues. Patients datasets were retrieved from the Oncomine database. OE: over-expressed, UE: under-expressed, Tot: total unique analyses. Numbers of significant analyses (p < 0.05; fold change >1.5) are shown inside the boxes and total numbers on the right side. Cell color indicates the best gene rank percentile for the analyses (red: over-expressed; blue: under-expressed). ELF5 mRNA expression as in Fig. 1e. Breast cancer datasets from Fig. 1e were displayed in details in Fig. 1f. g The expression of ELF5 in breast cancer based on breast cancer subclasses and data from http://ualcan.path.uab.edu/.
Fig. 1 Identification of ELF5 from p300 interaction network. a Silver-staining of p300 interacted protein. MCF7 cell lysis and T47D cell lysis were prepared and subjected to affinity purification using anti-p300 antibody or normal IgG. The purified proteins were resolved by SDS-PAGE and visualized by silver-staining. The protein bands were excised and analyzed by mass spectrometry. b ELF5 was immunoprecipitated with p300. Whole-cell lysates from T47D cells were subjected to co-immunoprecipitation performed with anti-p300 antibody or normal IgG followed by immunoblotting with performed with the indicated antibodies. Enrichment analysis (c) and cluster analysis (d) of biological processes according to the results of mass spectrometry. The graphs were downloaded from http://metascape.org/. e, f Comparison of ELF5 mRNA expression in healthy and various cancer tissues. Patients datasets were retrieved from the Oncomine database. OE: over-expressed, UE: under-expressed, Tot: total unique analyses. Numbers of significant analyses (p < 0.05; fold change >1.5) are shown inside the boxes and total numbers on the right side. Cell color indicates the best gene rank percentile for the analyses (red: over-expressed; blue: under-expressed). ELF5 mRNA expression as in Fig. 1e. Breast cancer datasets from Fig. 1e were displayed in details in Fig. 1f. g The expression of ELF5 in breast cancer based on breast cancer subclasses and data from http://ualcan.path.uab.edu/.CC BY · PubMed Central
Fig. 2 Acetylation of ELF5 by acetylatyltransferase p300. Acetylation of endogenous ELF5. a Lysates of T47D cells was immunoprecipitated with an anti-acetylated-lysine (AcK) antibody (Ab) or normal IgG, followed by western blot performed with anti-ELF5 Ab. b Lysates of T47D cells was immunoprecipitated with an anti-ELF5 Ab or normal IgG, followed by western blot performed with anti-AcK Ab. c p300-mediated acetylation of ELF5. HEK293T cells were co-transfected with Flag-ELF5 and different HA-tagged HATs, HA-p300, HA-PCAF, HA-GCN5, or HA-Tip60, and cell lysate was immunoprecipitated with anti-Flag affinity gel and immunoblotted with the anti-AcK Ab. d p300-mediated acetylation of ELF5 in a dose-dependent manner. HEK293T cells were co-transfected with Flag-ELF5 and increasing amounts of HA-p300. After 48 h of transfection, the cell lysates were subjected to co-immunoprecipitation with anti-Flag Ab and immunoblotted with the anti-AcK Ab. e Top: A model for full-length p300 showing all the different domains. It was compiled based on several recent analyses, and the catalytic acetyltransferase domain corresponding to residues 1281–1664. Bottom: A model for full-length p300 with single substitutions that inactivate acetyltransferase catalytic activity. f Acetylation of ELF5 by p300 depended on its intrinsic KAT activity. HEK293T cells were co-transfected with Flag-ELF5 and p300 or its catalytic mutant, and the cell lysate was subjected to co-immunoprecipitation with anti-Flag affinity gel and immunoblotted with the anti-AcK Ab. g Effect of p300 knockdown on the acetylation of ELF5. T47D cells were transfected with siRNA targeting EP300 and then immunoprecipitated with an anti-ELF5 antibody, followed by western blot with anti-AcK Ab. h Effect of ELF5 acetylation in the presence of p300 inhibitors. T47D cells were treated without or with Garcinol (10 μM), or C646 (10 μM) for 6 h and then immunoprecipitated with an anti-ELF5 Ab or normal IgG, followed by western blot with anti-AcK Ab. i Acetylation of ELF5 by p300 as detected by in vitro acetylation assay. GST-ELF5 fusion protein was affinity-purified and quantified by in vitro acetylation assay. The reaction mixture was subjected to SDS-PAGE and immunoblotted with anti-AcK Ab. Purified GST-ELF5 was examined by Coomassie blue staining.
Fig. 2 Acetylation of ELF5 by acetylatyltransferase p300. Acetylation of endogenous ELF5. a Lysates of T47D cells was immunoprecipitated with an anti-acetylated-lysine (AcK) antibody (Ab) or normal IgG, followed by western blot performed with anti-ELF5 Ab. b Lysates of T47D cells was immunoprecipitated with an anti-ELF5 Ab or normal IgG, followed by western blot performed with anti-AcK Ab. c p300-mediated acetylation of ELF5. HEK293T cells were co-transfected with Flag-ELF5 and different HA-tagged HATs, HA-p300, HA-PCAF, HA-GCN5, or HA-Tip60, and cell lysate was immunoprecipitated with anti-Flag affinity gel and immunoblotted with the anti-AcK Ab. d p300-mediated acetylation of ELF5 in a dose-dependent manner. HEK293T cells were co-transfected with Flag-ELF5 and increasing amounts of HA-p300. After 48 h of transfection, the cell lysates were subjected to co-immunoprecipitation with anti-Flag Ab and immunoblotted with the anti-AcK Ab. e Top: A model for full-length p300 showing all the different domains. It was compiled based on several recent analyses, and the catalytic acetyltransferase domain corresponding to residues 1281–1664. Bottom: A model for full-length p300 with single substitutions that inactivate acetyltransferase catalytic activity. f Acetylation of ELF5 by p300 depended on its intrinsic KAT activity. HEK293T cells were co-transfected with Flag-ELF5 and p300 or its catalytic mutant, and the cell lysate was subjected to co-immunoprecipitation with anti-Flag affinity gel and immunoblotted with the anti-AcK Ab. g Effect of p300 knockdown on the acetylation of ELF5. T47D cells were transfected with siRNA targeting EP300 and then immunoprecipitated with an anti-ELF5 antibody, followed by western blot with anti-AcK Ab. h Effect of ELF5 acetylation in the presence of p300 inhibitors. T47D cells were treated without or with Garcinol (10 μM), or C646 (10 μM) for 6 h and then immunoprecipitated with an anti-ELF5 Ab or normal IgG, followed by western blot with anti-AcK Ab. i Acetylation of ELF5 by p300 as detected by in vitro acetylation assay. GST-ELF5 fusion protein was affinity-purified and quantified by in vitro acetylation assay. The reaction mixture was subjected to SDS-PAGE and immunoblotted with anti-AcK Ab. Purified GST-ELF5 was examined by Coomassie blue staining.CC BY · PubMed Central
Fig. 3 ELF5 is acetylated at K130, K134, K143, K197, K228 and K245. a Diagram outlining the steps involved in the preparation of sample for mass spectrometry (MS) to identify the acetylation lysine sites of ELF5. b Mass spectrometry identification of ELF5 acetylation sites in HEK293T cells transfected with expression plasmids for Flag-ELF5 and HA-p300. c MS analysis of the ELF5-derived peptides containing acetylated K130. d Diagram showing the acetylation sites of ELF5 that were mutated. e Effects of lysine to arginine at putative acetylated lysine residues on the acetylation of ELF5. Hela cells co-transfected with Flag-ELF5 WT or mutant Flag-ELF5 plus HA-p300 or not, cell lysis was immunoprecipitated with anti-Flag affinity gel and immunoblotted with the anti-AcK Ab. f Quantitative analyses of the acetylation of ELF5 WT and mutants. g The acetylation of ELF5 6KR was abolished. HEK293T cells co-transfected Flag-ELF5 WT or Flag-ELF5 6KR without and with HA-p300. Cell lysis was immunoprecipitated with anti-Flag affinity gel and immunoblotted with the anti-AcK Ab.
Fig. 3 ELF5 is acetylated at K130, K134, K143, K197, K228 and K245. a Diagram outlining the steps involved in the preparation of sample for mass spectrometry (MS) to identify the acetylation lysine sites of ELF5. b Mass spectrometry identification of ELF5 acetylation sites in HEK293T cells transfected with expression plasmids for Flag-ELF5 and HA-p300. c MS analysis of the ELF5-derived peptides containing acetylated K130. d Diagram showing the acetylation sites of ELF5 that were mutated. e Effects of lysine to arginine at putative acetylated lysine residues on the acetylation of ELF5. Hela cells co-transfected with Flag-ELF5 WT or mutant Flag-ELF5 plus HA-p300 or not, cell lysis was immunoprecipitated with anti-Flag affinity gel and immunoblotted with the anti-AcK Ab. f Quantitative analyses of the acetylation of ELF5 WT and mutants. g The acetylation of ELF5 6KR was abolished. HEK293T cells co-transfected Flag-ELF5 WT or Flag-ELF5 6KR without and with HA-p300. Cell lysis was immunoprecipitated with anti-Flag affinity gel and immunoblotted with the anti-AcK Ab.CC BY · PubMed Central
Fig. 4 SIRT6 specifically interacts with and deacetylates ELF5. a Deacetylase inhibitors increased the acetylation level of ELF5. HEK293T cells were treated without and with TSA or NAM, or both TSA and NAM, and cell extract was immunoprecipitated with an anti-ELF5 antibody, followed by western blot with the anti-AcK Ab. b Exogenous ELF5 interacted with SIRT6. HA-ELF5 was overexpressed with different Flag-Sirtuin in HEK293T cells, followed by immunoprecipitation with anti-Flag affinity gel and western blot with anti-HA Ab. c Exogenous ELF5 bound to wild type SIRT6. Flag-ELF5 was co-expressed with GFP-SIRT6 or the catalytic mutant H133Y, and the cell extract was subjected to affinity purification with anti-Flag affinity gel, followed by Western blot with the indicated antibodies. Endogenous interaction between ELF5 and SIRT6 in T47D cells as detected by IP. T47D cells were subjected to immunoprecipitation with anti-SIRT6 Ab or normal IgG followed by Western blot with anti-ELF5 Ab (d). T47D cells were subjected to immunoprecipitation with anti-ELF5 Ab or normal IgG followed by Western blot with anti-SIRT6 Ab (e). f Interaction between ELF5 and SIRT6 as demonstrated by GST-pulldown assay. Extract of HEK293T cells overexpressing GFP-SIRT6 was subjected to GST-pulldown assays with GST or GST- ELF5. g Effects of SIRT6 knockdown on the acetylation of ELF5. T47D cells were transfected with siRNA targeting SIRT6 and then immunoprecipitated with an anti-ELF5 Ab, followed by western blot with anti-AcK Ab. h Effect of ELF5 acetylation in the presence of SIRT6 inhibitors. T47D cells were treated without or with NAM (5 mM), or OSS_128167 (200 μM) for 6 h and then immunoprecipitated with an anti-ELF5 Ab or normal IgG, followed by western blot with anti-AcK Ab. i Deacetylation of ELF5 by SIRT6 as demonstrated by in vitro deacetylation assay. GST-ELF5 was affinity-purified and measured by in vitro deacetylation assays. Pre-acetylated GST-ELF5 was incubated with immunoprecipitated Flag-SIRT6 WT or Flag-SIRT6 H133Y in the presence of NAD+. The reaction mixtures were subjected to SDS-PAGE and immunoblotted with anti-AcK Ab. The purified GST fusion proteins were examined by Coomassie blue staining.
Fig. 4 SIRT6 specifically interacts with and deacetylates ELF5. a Deacetylase inhibitors increased the acetylation level of ELF5. HEK293T cells were treated without and with TSA or NAM, or both TSA and NAM, and cell extract was immunoprecipitated with an anti-ELF5 antibody, followed by western blot with the anti-AcK Ab. b Exogenous ELF5 interacted with SIRT6. HA-ELF5 was overexpressed with different Flag-Sirtuin in HEK293T cells, followed by immunoprecipitation with anti-Flag affinity gel and western blot with anti-HA Ab. c Exogenous ELF5 bound to wild type SIRT6. Flag-ELF5 was co-expressed with GFP-SIRT6 or the catalytic mutant H133Y, and the cell extract was subjected to affinity purification with anti-Flag affinity gel, followed by Western blot with the indicated antibodies. Endogenous interaction between ELF5 and SIRT6 in T47D cells as detected by IP. T47D cells were subjected to immunoprecipitation with anti-SIRT6 Ab or normal IgG followed by Western blot with anti-ELF5 Ab (d). T47D cells were subjected to immunoprecipitation with anti-ELF5 Ab or normal IgG followed by Western blot with anti-SIRT6 Ab (e). f Interaction between ELF5 and SIRT6 as demonstrated by GST-pulldown assay. Extract of HEK293T cells overexpressing GFP-SIRT6 was subjected to GST-pulldown assays with GST or GST- ELF5. g Effects of SIRT6 knockdown on the acetylation of ELF5. T47D cells were transfected with siRNA targeting SIRT6 and then immunoprecipitated with an anti-ELF5 Ab, followed by western blot with anti-AcK Ab. h Effect of ELF5 acetylation in the presence of SIRT6 inhibitors. T47D cells were treated without or with NAM (5 mM), or OSS_128167 (200 μM) for 6 h and then immunoprecipitated with an anti-ELF5 Ab or normal IgG, followed by western blot with anti-AcK Ab. i Deacetylation of ELF5 by SIRT6 as demonstrated by in vitro deacetylation assay. GST-ELF5 was affinity-purified and measured by in vitro deacetylation assays. Pre-acetylated GST-ELF5 was incubated with immunoprecipitated Flag-SIRT6 WT or Flag-SIRT6 H133Y in the presence of NAD+. The reaction mixtures were subjected to SDS-PAGE and immunoblotted with anti-AcK Ab. The purified GST fusion proteins were examined by Coomassie blue staining.CC BY · PubMed Central
Fig. 5 Acetylation promotes the proteasome-mediated degradation of ELF5. a Inhibition of deacetylation and protein synthesis on the protein level of ELF5. HEK293T cells were treated without and with 2 μM TSA and 5 mM NAM in the absence or presence of 20 μM MG132. Endogenous ELF5 was probed by anti-ELF5 Ab. b NAM- and TSA-mediated regulation of the ELF5 ubiquitination. Ubiquitination of Flag-ELF5 expressed in HEK293T cells the absence and presence of NAM + TSA with MG132. c Quantitation of the ubiquitination levels of Flag-ELF5 WT, Flag-ELF5 6KR, and Flag-ELF5 6KQ in HEK293T cells. d, e Half-lives of ELF5 and mutants. HEK293T cells expressing GFP-ELF5-WT, GFP-ELF5-6KR, or GFP-ELF5-6KQ were treated with 50 μM Cycloheximide, and the expression levels of these proteins were analyzed by western blot with anti-GFP Ab. The graph shown represents the ELF5 half-lives in Fig. 5e. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01. f, g The expression of ELF5 and SIRT6 in human breast cancer tissues. Representative images tissue samples from breast cancer patients showing the expression levels of ELF5 and SIRT6 as assessed by immunohistochemistry. Both ELF5 and SIRT6 levels were classified as low, medium, or high based on the intensities of their IHC staining, and the percentages of patients classified in each category are depicted in the histogram in Fig. 5g.
Fig. 5 Acetylation promotes the proteasome-mediated degradation of ELF5. a Inhibition of deacetylation and protein synthesis on the protein level of ELF5. HEK293T cells were treated without and with 2 μM TSA and 5 mM NAM in the absence or presence of 20 μM MG132. Endogenous ELF5 was probed by anti-ELF5 Ab. b NAM- and TSA-mediated regulation of the ELF5 ubiquitination. Ubiquitination of Flag-ELF5 expressed in HEK293T cells the absence and presence of NAM + TSA with MG132. c Quantitation of the ubiquitination levels of Flag-ELF5 WT, Flag-ELF5 6KR, and Flag-ELF5 6KQ in HEK293T cells. d, e Half-lives of ELF5 and mutants. HEK293T cells expressing GFP-ELF5-WT, GFP-ELF5-6KR, or GFP-ELF5-6KQ were treated with 50 μM Cycloheximide, and the expression levels of these proteins were analyzed by western blot with anti-GFP Ab. The graph shown represents the ELF5 half-lives in Fig. 5e. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01. f, g The expression of ELF5 and SIRT6 in human breast cancer tissues. Representative images tissue samples from breast cancer patients showing the expression levels of ELF5 and SIRT6 as assessed by immunohistochemistry. Both ELF5 and SIRT6 levels were classified as low, medium, or high based on the intensities of their IHC staining, and the percentages of patients classified in each category are depicted in the histogram in Fig. 5g.CC BY · PubMed Central
Fig. 6 Inhibition of breast cancer cell proliferation and tumorigenesis by ELF5 acetylation. a Growth curves of MCF7 cells that stably expressed GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ as measured by CCK8 assay. Control cells were transfected with just the pEGFP-C1. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01; ns, no significance. b Colony formation of MCF7 cells that stably expressed GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ as measured by crystal violet staining assay. Control MCF7 cells were transfected with just the vector pEGFP-C1. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01; ns, no significance. c Anchorage-independent growth activity of MCF7 cells as measured by soft-agar colony culture assay. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01; ns, no significance. d Image showing the tumor formed in xenograft mice. e, f Weight and growth of tumor induced in mice by subcutaneously implanted MCF7 cells (5 × 106 cells injected per mice) that stably expressed GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ. Control MCF7 cells were transfected with just the vector pEGFP-C1. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01; ns, no significance.
Fig. 6 Inhibition of breast cancer cell proliferation and tumorigenesis by ELF5 acetylation. a Growth curves of MCF7 cells that stably expressed GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ as measured by CCK8 assay. Control cells were transfected with just the pEGFP-C1. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01; ns, no significance. b Colony formation of MCF7 cells that stably expressed GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ as measured by crystal violet staining assay. Control MCF7 cells were transfected with just the vector pEGFP-C1. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01; ns, no significance. c Anchorage-independent growth activity of MCF7 cells as measured by soft-agar colony culture assay. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01; ns, no significance. d Image showing the tumor formed in xenograft mice. e, f Weight and growth of tumor induced in mice by subcutaneously implanted MCF7 cells (5 × 106 cells injected per mice) that stably expressed GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ. Control MCF7 cells were transfected with just the vector pEGFP-C1. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01; ns, no significance.CC BY · PubMed Central
Fig. 7 Inhibition of CCND1 transcription by ELF5 acetylation. a Flow cytometry analysis of the cell cycle showing the distribution of MCF7 cells stably transfected with GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ or control vector. b Western-blot detection of cyclins and CDKs expression in MCF7 cells that overexpressed with GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ or the control vector. c Schematic representation of the conserved ELF5-binding motif and on CCND1 potential promoter region. d Regions of CCND1 promoter physically associated with ELF5 as analyzed by ChIP assay. Top: schematic illustration of the PCR-amplified fragments of CCND1 promoter; bottom: ChIP assay was carried out using anti-Flag antibody to screen for ELF5-bound CCND1 promoter regions in HEK293T cells. e Effect of mutations within the ELF5-binding site of CCND1 promoter on its activity. CCND1 promoter with a site-specific mutation within the ELF5-binding site was fused to a luciferase reporter gene. MCF-7 cells transfected with such construct and either Flag-ELF5 WT, Flag-ELF5 6KR, Flag-ELF5-6KQ or the vector pEGFP-C1 were subjected to luciferase activity assay. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01. f Growth curves of MCF7 cells that stably overexpressed with GFP-ELF5 without or with HA-cyclin D1 overexpression as measured by CCK8 assay. *p < 0.05; **p < 0.01; ns, no significance, compared with cells transfected with just the pEGFP-C1 vector. g Top: T47D cells expressing a shCtrl or shELF5 were analyzed for Cyclin D1 protein level. Bottom: Growth curves of T47D cells expressing a shCtrl or shELF5 without or with palbociclib treatment as measured by CCK8 assay. *p < 0.05; **p < 0.01; ns, no significance. h Correlation between Cyclin D1 and ELF5 expression in breast cancer tissues. Two-side χ2-test was used for statistical analysis. i Representative images of tissue samples from breast cancer patients showing the expression levels of ELF5 and Cyclin D1 as assessed by immunohistochemistry. Both ELF5 and Cyclin D1 levels were classified as low, medium, or high based on the intensities of the IHC staining. j Proposed model depicting the regulation of ELF5 by acetylation. In this model, ELF5 is acetylated by acetyltransferase p300 and deacetylated by deacetylase SIRT6. Acetylation of ELF5 increases its capacity to suppress breast cancer proliferation by suppressing the transcription of its target gene CCND1.
Fig. 7 Inhibition of CCND1 transcription by ELF5 acetylation. a Flow cytometry analysis of the cell cycle showing the distribution of MCF7 cells stably transfected with GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ or control vector. b Western-blot detection of cyclins and CDKs expression in MCF7 cells that overexpressed with GFP-ELF5 WT, GFP-ELF5 6KR, GFP-ELF5-6KQ or the control vector. c Schematic representation of the conserved ELF5-binding motif and on CCND1 potential promoter region. d Regions of CCND1 promoter physically associated with ELF5 as analyzed by ChIP assay. Top: schematic illustration of the PCR-amplified fragments of CCND1 promoter; bottom: ChIP assay was carried out using anti-Flag antibody to screen for ELF5-bound CCND1 promoter regions in HEK293T cells. e Effect of mutations within the ELF5-binding site of CCND1 promoter on its activity. CCND1 promoter with a site-specific mutation within the ELF5-binding site was fused to a luciferase reporter gene. MCF-7 cells transfected with such construct and either Flag-ELF5 WT, Flag-ELF5 6KR, Flag-ELF5-6KQ or the vector pEGFP-C1 were subjected to luciferase activity assay. Data are the means ± SDs from three determinations. *p < 0.05; **p < 0.01. f Growth curves of MCF7 cells that stably overexpressed with GFP-ELF5 without or with HA-cyclin D1 overexpression as measured by CCK8 assay. *p < 0.05; **p < 0.01; ns, no significance, compared with cells transfected with just the pEGFP-C1 vector. g Top: T47D cells expressing a shCtrl or shELF5 were analyzed for Cyclin D1 protein level. Bottom: Growth curves of T47D cells expressing a shCtrl or shELF5 without or with palbociclib treatment as measured by CCK8 assay. *p < 0.05; **p < 0.01; ns, no significance. h Correlation between Cyclin D1 and ELF5 expression in breast cancer tissues. Two-side χ2-test was used for statistical analysis. i Representative images of tissue samples from breast cancer patients showing the expression levels of ELF5 and Cyclin D1 as assessed by immunohistochemistry. Both ELF5 and Cyclin D1 levels were classified as low, medium, or high based on the intensities of the IHC staining. j Proposed model depicting the regulation of ELF5 by acetylation. In this model, ELF5 is acetylated by acetyltransferase p300 and deacetylated by deacetylase SIRT6. Acetylation of ELF5 increases its capacity to suppress breast cancer proliferation by suppressing the transcription of its target gene CCND1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

See all 20

Metadata

Authors
Li, X., Li, S., Li, B., Li, Y., Aman, S., Xia, K., Yang, Y., Ahmad, B., & Wu, H.
Affiliations
Dalian University of Technology (CN)
Corresponding author
Wu, Huijian
Venue
npj Precision Oncology
Published
2021-03-19
Volume
5
Issue
1
Pages
20-20
ISSN
2397-768X (ISSN-L)
OpenAlex
W3137425419
Cited by
20
References
71
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 3
FWCI
1.10
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81872263, 81672793)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
ELF5, protein acetylation, breast cancer progression, P300, SIRT6, ubiquitination, protein degradation, CCND1, cyclin D1, ETS transcription factors, tumor suppressor, acetylation sites

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1. https://app.cochat.ai/papers/10.1038/s41698-021-00158-3
The paper
Li, X., Li, S., Li, B., Li, Y., Aman, S., Xia, K., Yang, Y., Ahmad, B., & Wu, H. (2021). Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1. npj Precision Oncology. https://doi.org/10.1038/s41698-021-00158-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.